BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 208 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,349 | +0.6% | 190,541 | 0.0% | 0.01% | 0.0% |
| Q2 2023 | $1,341 | +70.2% | 190,541 | +101.8% | 0.01% | +50.0% |
| Q1 2023 | $788 | -30.8% | 94,440 | -4.7% | 0.01% | -33.3% |
| Q4 2022 | $1,138 | -99.9% | 99,086 | -5.5% | 0.01% | -10.0% |
| Q3 2022 | $1,321,000 | +19.1% | 104,829 | 0.0% | 0.01% | +25.0% |
| Q2 2022 | $1,109,000 | -35.0% | 104,829 | 0.0% | 0.01% | -20.0% |
| Q1 2022 | $1,705,000 | +17.9% | 104,829 | 0.0% | 0.01% | +42.9% |
| Q4 2021 | $1,446,000 | -4.0% | 104,829 | 0.0% | 0.01% | -12.5% |
| Q3 2021 | $1,506,000 | – | 104,829 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |